Premium
Oral quercetin supplementation and blood oxidative stress during ultra‐marathon competition
Author(s) -
Quindry John C,
McAnulty Steve,
Hudson Matthew,
Hosick Peter,
Dumke Chuck,
McAnulty Lisa,
Henson Dru,
Nieman David
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.5.a173-b
Subject(s) - quercetin , oxidative stress , antioxidant , placebo , trolox , trolox equivalent antioxidant capacity , ferric reducing ability of plasma , chemistry , medicine , pharmacology , endocrinology , biochemistry , antioxidant capacity , alternative medicine , pathology
Previous research indicates that prolonged exercise results in blood oxidative stress. We investigated the efficacy of oral quercetin supplementation, a naturally occurring compound with known antioxidant properties, as a potential countermeasure against blood oxidative stress during an ultra‐marathon competition. In double blind fashion, 63 subjects received either oral quercetin (250 mg, 4x/day; 1000 mg/day total) or placebo 3‐weeks prior to and during the Western States 100 mile trail run. Blood drawn before and immediately following (quercetin finishers n=18, placebo finishers n=21) the event was analyzed for changes in blood redox status and oxidative damage. Results show that in response to the ultra‐marathon challenge, aqueous phase antioxidant capacity (ferric reducing ability of plasma, FRAP) was similarly elevated in athletes from both quercetin and placebo treatments and likely reflects significant increases in plasma urate levels. Alternately, trolox equivalent antioxidant capacity (TEAC) was not altered by exercise or quercetin based on a significance level of p < 0.05. Accordingly, neither F2‐isoprostances nor lipid hydroperoxides were influenced by either exercise or quercetin supplementation. These findings indicate that oral quercetin supplementation does not appear to alter the lipid or aqueous phase antioxidant capacity of the blood plasma during an ultra‐marathon challenge. Supported by a grant from DARPA, award number W911NF‐06‐0014.